Abstract
Background Hepatocellular carcinoma (HCC), is a prevalent and fatal malignancy originating from hepatic cells with a consistently rising incidence in recent decades. In this study, we aim to identify potential prognostic biomarkers and reveal new mechanism in HCC.
Methods HCC-related datasets (GSE45267 and GSE49515) and TCGA information were downloaded for DEGs, and the common DEGs were WGCNA, protein-protein interaction network (PPI), risk model, expression, survival and prognostic nomogram to determine the key gene related to HCC. Further, the key gene was analyzed by clinical feature analysis, immunoassay and cell experiments to investigate its exact role in HCC.
Results Based on the above comprehensive analysis, we targeted the key gene PAK1-interacting protein 1(PAK1IP1) with a good prognostic value in HCC. PAK1IP1 was remarkably increased in tumor samples than normal samples, which might be related to immune cell infiltration in liver cancer. It was up-regulated in HCC cells, and its knockdown could suppress HCC proliferation and migration. Besides, ELISA and flow cytometry showed that PAK1IP1 could regulate Lipopolysaccharide (LPS)-induced pyroptosis of HCC cells. Knocking down PAK1IP1 could induce CASP-3-dependent pyroptosis in HCC cells to suppress the development of HCC.
Conclusion To sum up, PAK1IP1 was identified as a promising prognostic biomarker, and knockdown of PAK1IP1 can induce CASP-3-dependent pyroptosis to suppress HCC development, which sheds new light on HCC tumorigenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
